AnaptysBio Inc (ANAB) is a biotechnology company that develops antibody therapeutics to address unmet medical needs in inflammation and immuno-oncology. The company's pipeline includes several clinical-stage drug candidates targeting inflammatory diseases, including severe adult asthma, atopic dermatitis, and eosinophilic upper airway diseases, as well as oncology indications such as anti-PD-1 agonists and tumor-specific antibody drug conjugates. AnaptysBio's proprietary antibody discovery platform, called SHM-XEL, enables the rapid identification of high-quality antibodies against complex drug targets. The company is headquartered in San Diego, California.
AnaptysBio Inc (ANAB) is a biotechnology company that develops antibody therapeutics to address unmet medical needs in inflammation and immuno-oncology. The company's pipeline includes several clinical-stage drug candidates targeting inflammatory diseases, including severe adult asthma, atopic dermatitis, and eosinophilic upper airway diseases, as well as oncology indications such as anti-PD-1 agonists and tumor-specific antibody drug conjugates. AnaptysBio's proprietary antibody discovery platform, called SHM-XEL, enables the rapid identification of high-quality antibodies against complex drug targets. The company is headquartered in San Diego, California.